Department of Internal Medicine, Internal Medicine Residency Program, Residency Program Office, Hamilton, Ontario, Canada.
Semin Thromb Hemost. 2012 Oct;38(7):702-10. doi: 10.1055/s-0032-1326788. Epub 2012 Oct 3.
Anticoagulant therapy reduces deaths and disability in patients with or at risk of both arterial and venous thromboembolism. Highly effective antithrombotic therapies now exist that reduce the risk of both arterial thrombosis and venous thrombosis. Anticoagulant strategies include platelet inhibition, using a variety of potent platelet inhibitors, and antithrombotic therapy, designed to interfere with thrombosis by blocking activation of the coagulation cascade. All anticoagulants increase the risk of bleeding. Older antithrombotic agents have, in most cases, effective antidotes and well-developed (although perhaps not very evidence-based) treatment strategies. Newer anticoagulants, and most antiplatelet drugs, do not have effective antidotes or well-tested reversal strategies. This narrative review will provide advice on the diagnosis and management of anticoagulant bleeding with a particular focus on the antithrombotic drugs, including warfarin, heparin, and the novel agents.
抗凝治疗可降低动脉和静脉血栓栓塞患者或有此风险患者的死亡率和残疾率。目前存在高效的抗血栓治疗方法,可降低动脉血栓形成和静脉血栓形成的风险。抗凝策略包括血小板抑制,使用各种强效血小板抑制剂,以及抗血栓治疗,旨在通过阻断凝血级联反应的激活来干扰血栓形成。所有抗凝剂都会增加出血风险。在大多数情况下,较老的抗血栓药物有有效的解毒剂和完善的(尽管可能不是非常基于证据)治疗策略。新型抗凝剂和大多数抗血小板药物没有有效的解毒剂或经过充分测试的逆转策略。本叙述性综述将提供关于抗凝出血的诊断和管理的建议,特别关注抗血栓药物,包括华法林、肝素和新型药物。